Peer-reviewed veterinary case report
Blood clotting problems in dogs with lymphoma - review
By Gorenstein, Tatiana Geraissate et al.·Published in Research in veterinary science·2025·Department of Veterinary Medicine and Surgery, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Hemostatic evaluation in dogs with lymphoma - Systematic review.
- Species:
- dog
Plain-English summary
A dog with lymphoma may have an increased risk of blood clots due to changes in their blood's ability to clot. This study found that while some blood tests like platelet counts were normal, other tests showed signs of hypercoagulability, meaning the blood was more likely to clot than usual. This is likely caused by the cancer and inflammation associated with it. It's important for pet owners to be aware of these risks, especially if their dog is undergoing chemotherapy, as treatment can affect blood dynamics. Regular monitoring and discussions with a veterinarian can help manage these risks effectively.
People also search for: dog lymphoma symptoms · dog blood clot risk lymphoma · dog chemotherapy side effects
Abstract
BACKGROUND: Lymphoma is characterized by clonal proliferation of malignant lymphocytes and it is the most common hematopoietic cancer in dogs. Affected patients may exhibit increased thrombotic risk due to cancer-associated dysregulation of hemostatic pathways, including tissue factor overexpression in tumor stroma, activation of plasminogen inhibitors and coagulation proteases and systemic inflammation. OBJECTIVES: This study aimed to evaluate the impact of lymphoma on hemostatic function in canine patients. METHODS: This review was elaborated in accordance with the Cochrane Handbook for Systematic Reviews (v6.3, 2022). Eligibility criteria encompassed original studies, published in databases, 1960-2024, assessing hemostatic variables in canine patients with confirmed diagnosis of lymphoma. Analyzed parameters included: platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, antithrombin (AT), fibrinogen degradation products (FDPs), D-dimer concentration, platelet aggregation and viscoelastic testing. RESULTS: Dogs with lymphoma demonstrated platelet counts, aPTT, and AT activity within reference intervals. Increased viscoelasticity and elevated FDPs/D-dimer levels, indicating hypercoagulability. CONCLUSIONS: Canine lymphoma is linked to an increased thrombotic risk, reflected by hypercoagulable profiles and elevated FDPs and D-dimers, likely driven by tumor-associated procoagulant activity and inflammation. Platelet dynamics are variable and influenced by chemotherapy, and comparisons are limited by lymphoma heterogeneity and study variability. Future research should standardize lymphoma classification, monitor hemostatic changes longitudinally, and correlate biomarkers with clinical outcomes to improve risk stratification and therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40934825/